Clinical Trial Update: Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

The Phase 1 safety and efficacy study of CI-135 CAR-T cells for relapsed or refractory acute myeloid leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CI-135 CAR-T Cells

Snippet

Sponsor: Beijing Boren Hospital | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: WITHDRAWN